Endocrine Abstracts

Somatostatin (SSTRs) and dopamine (DRs) receptors are expressed in adrenal tumors. It has been demonstrated in pituitary and neuroendocrine tumors that somatostatin-dopamine chimeric molecules, namely dopastatins, which bind both somatostatin (SST2 and/or SST5) and dopamine (D2) receptors, exert a more potent action compared with the single receptor agonists in experimental settings. The aims of this study were to evaluate the expression of DRs and SSTRs, and the effects of do...

The dopamine agonist cabergoline has been found to be effective in inducing normalization of cortisol secretion in 25–50% of patients with Cushing’s disease after long-term treatment. Moreover, tumor shrinkage have been documented in selected patients with pituitary corticotroph tumors. The aim of the present study was to evaluate the effect of cabergoline withdrawal in patients with a stable normalization of cortisol secretion and stable or absent visualization of p...

Generously supported by IPSEN)-->Hyperprolactinemia is reportedly associated with impaired metabolic profile, particularly in patients with concomitant hypogonadism. The current study aimed at investigating the effects of 12 and 24 month-continuous cabergoline (CAB) treatment on metabolic profile in male hyperprolactinemic patients. Thirty-two men with prolactinomas, including 22 with testosterone < 8 nmol/l (HG, 69%) and 10 with...

Introduction: Generously supported by IPSEN)-->Hyperprolactinemia (HPRL) is associated with an impaired metabolic profile, particularly in patients with hypogonadism. This study aimed to: i) investigate the effects of short and long treatment with cabergoline (CAB) on the prevalence of metabolic syndrome (MS) and insulin sensitivity and ii) to evaluate the impact of gonadal function on metabolic changes, in male patients with HPRL.</...

Introduction: Generously supported by IPSEN)-->Glucocorticoids (GC) have a stimulatory effect on neutrophils and an inhibitory effect on the other leukocyte subpopulations. A potential stimulatory effect on erythropoiesis has been also hypothesized. The aim of our study was to evaluate the effect of pasireotide treatment on hemochrome parameters in patients with endogenous pituitary-dependent glucocorticoid excess or Cushing’s d...

The GH-receptor antagonist PEG, used as monotherapy or in combination to SA, has been demonstrated to normalize IGF1 levels in up to 90% of acromegalic patients after unsuccessful surgery and/or radiotherapy and resistant to conventional SA treatment. The aim of this study is to evaluate the efficacy and safety of combined treatment with SA plus PEG in a cohort of acromegalic patients resistant to conventional SA therapy. Thirty-two acromegalic patients (17 M, 15 F, age 39.6&#...